The prognostic role of ploidy status, S phase fraction, estrogen and progesterone receptor status, and the expression of p53 and erbB-2 protein in male breast carcinoma (MBC) remains controversial. The primary objective of this study was to determine which of the common prognostic factors for female breast cancer predict prognosis in MBC. A secondary objective was to assess the impact of comorbid illnesses on survival. A retrospective review of demographic data, surgical treatment, pathological staging, adjuvant treatment and follow-up was completed for 16 patients with MBC (1 intraductal and 15 invasive). Formalin-fixed, paraffin-embedded tissue was processed for ploidy, S phase fraction, and immunohistochemical detection of estrogen and progesterone receptors plus expression of p53 and erbB-2 protein. Six of 15 patients with infiltrating ductal carcinoma are currently alive without evidence of disease and a median survival of 61 months. Nine patients died after a median survival of 52 months, with 6 patients having no evidence of recurrent breast cancer. Two of 3 deaths secondary to advanced breast cancer occurred in patients who initially presented with T4 lesions and were staged IIIB. Two of 15 tumors were erbB-2 positive, whereas only 1 tested weakly positive for p53 protein. We observed that MBCs express erbB-2 and p53 proteins infrequently. Neither ploidy status, S phase fraction, nor erbB-2/p53 status provided any apparent improvement in establishing prognosis beyond routine pathological staging. Advanced TNM stage was associated with diminished survival. The majority of MBCs express estrogen and progesterone receptors. Survivals in MBC were reduced in association with comorbid medical conditions.
Get full access to this article
View all access options for this article.
References
1.
BavafaS, ReyesCV, ChoudhuryAM. Male breast carcinoma: An updated experience at a Veterans Administration hospital and review of the literature. J Surg Oncol1983;24:41–5.
2.
LandisSH, MurrayT, BoldenS, WingoPA. Cancer Statistics, 1999. CA Cancer J Clin1999;49:8–31.
3.
ElstonCW, EllisIO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term followup. Histopathology1991;19:403–10.
4.
HedleyD, FriedlanderM, TaylorI, . Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem1983;31: 1333–5.
5.
FlemingID, CooperJS, HensonDE, , eds. American Joint Committee on Cancer Staging Manual, 5th Ed. Philadelphia: JB Lippincott, 1997.
6.
DoneganEL, Perez-MesaCM. Carcinoma of the male breast: A 30-year review of 28 cases. Arch Surg1973;106:272–9.
7.
CutuliB, LacrozeM, DilhuydyJM, . Male breast cancer: Results of the treatments and prognostic factors in 397 cases. Eur J Cancer1995;31A:1960–1964.
8.
IhekwabaFN. Breast cancer in men in black Africa: A report of 73 cases. J R Coll Surg Edinb1994;39:344–7.
9.
LeforAT, NumannPJ. Carcinoma of the breast in men. NY State J Med1988;88:293–6.
10.
CrocettiE, BuiattiE. Male breast cancer: Incidence, mortality and survival rates from an Italian population-based series. Eur J Cancer1994;30A: 1732–1733.
11.
StiererM, RosenH, WeitensfelderW, . Male breast cancer: Austrian experience. World J Surg1995;19:687–93.
12.
JoshiMG, LeeAKC, LodaM, . Male breast carcinoma: An evaluation of prognostic factors contributing to a poorer outcome. Cancer1996;77:490–8.
13.
SalvadoriB, SaccozziR, ManzariA, . Prognosis of breast cancer in males: An analysis of 170 cases. Eur J Cancer1994;30A:930–5.
14.
WainwrightJ. Carcinoma of the male breast: Clinical and pathological study. Arch Surg1927;14:836–59.
15.
CrichlowRW. Carcinoma of the male breast. Surg Gynecol Obstet1972;134:1011–9.
16.
HellerKS, RosenPP, SchottenfeldD, . Male breast cancer: A clinicopathologic study of 97 cases. Ann Surg1978; 188:60–5.
17.
NorrisHJ, TaylorHB. Carcinoma of the male breast. Cancer1969;23:1428–35.
18.
van GeelAN, van SlootenEA, MavrunacM, HartAAM. A retrospective study of male breast cancer in Holland. Br J Surg1985;72:724–7.
19.
VercoutereAL, O'ConnellTX. Carcinoma of the male breast. Arch Surg1984; 119:1301–4.
20.
GuineeVF, OlssonH, MollerT, ShallenbergerRC, . The prognosis of breast cancer in males. Cancer1993;71:154–61.
21.
WillsherPC, LeachIH, EllisIO, . A comparison outcome of male breast cancer with female breast cancer. Am J Surg1997;173:185–8.
22.
ErlichmanC, MurphyKC, ElhakimT. Male breast cancer: A 13-year review of 89 patients. J Clin Oncol1984;2:903–9.
23.
HultbornR, FribergS, HultbomKA. Male breast carcinoma: A study of the total material reported to the Swedish Cancer Registry 1958–1967 with respect to clinical and histopathologic parameters. Acta Oncologica1987;26:241–56.
24.
RudanI, RudanN, StrnadM. Differences between male and female breast cancer. I. Epidemiological features. Acta Med Croatica1995;49:117–20.
25.
SascoAJ, FontaniereB. A population-based series of 10 males breast cancer cases. Eur J Cancer1991;27:1713.
26.
AjayiDOS, OsegbeDN, AdemiluyiSA. Carcinoma of the male breast in West Africans and a review of world literature. Cancer1982;50:1664–7.
27.
WilliamsWL, PowersM, WagmanLD. Cancer of the male breast: A review. J Natl Med Assoc1996;88:439–43.
28.
ShuklaNK, SeenuV, GoelAK, . Male breast cancer: A retrospective study from a regional cancer center in northern India. J Surg Oncol1996;61:143–8.
29.
GuptaS, PantGC, GuptaS. Male breast cancer. J Surg Oncol1981;16:149–57.
30.
SascoAJ, LowenfelsAB, Pasker-DeJongP. Review article: Epidemiology of male breast cancer: A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer1993;53:538–49.
31.
CasagrandeJT, HanischR, PikeMC, . A case-control study of male breast cancer. Cancer Res1988;48:1326–30.
32.
MisraSP, MisraV, DwivediM. Cancer of the breast in a male cirrhotic: Is there an association between the two?Am J Gastroenterol1996;91:380–2.
33.
El-GazayerliMM, Abdel-AzizAS. On bilharziasis and male breast cancer in Egypt: A preliminary report and review of the literature. Br J Cancer1963:17:566–71.
34.
HalstedWS. The results of radical operations for cure of cancer of the breast performed at the Johns Hopkins Hospital. Ann Surg1894;20:497.
35.
NemotoT, VanaJ, BedwaniRN, . Management and survival of female breast cancer: Results of a national survey by American College of Surgeons. Cancer1980;45:2917–24.
36.
FisherB, AndersonS, RedmondCK, . Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med1995; 333:1456–61.
37.
DigenisAG, RossCB, MorrisonJG, . Carcinoma of the male breast: A review of 41 cases. South Med J1990;83:1162–7.
38.
OurielK, LotzeMT, HinshawJR. Prognostic factors of carcinoma of the male breast. Surg Gynecol Obstet1984; 159: 373–6.
39.
WinchesterDJ. Male breast cancer. Semin Surg Oncol1996;12:364–9.
40.
DoneganWL. Cancer of the male breast. In: DoneganWL, SprattJS. Cancer of the Breast, 4th Ed. Philadelphia: WB Saunders Co, 1995, pp 765–77.
41.
RibieroG. Male breast carcinoma: A review of 301 cases from the Christie Hospital & Holt Radium Institute, Manchester. Br J Cancer1985;51:115–9.
42.
HodsonGR, UrdanetaLF, Al-JurfAS, JochimsenPR. Male breast carcinoma. Am Surg1985;51:47–9.
43.
BorgenPI, WongGY, VlamisV, . Current management of male breast cancer: A review of 104 cases. Ann Surg1992;215: 451–9.
44.
NanceKV, ReddickRL. In situ and infiltrating lobular carcinoma of the male breast. Hum Pathol1989;20:1220–2.
45.
SanchezAG, VillanuevaAG, RedondoC. Lobular carcinoma of the breast in a patient with Klinefelter's syndrome: A case with bilateral, histologically different breast tumors. Cancer1986; 57:1181–3.
46.
DoneganWL, RedlichPN. Breast cancer in men. Surg Clin North Am1996;76:343–63.
47.
WillsherPC, LeachIH, EllisIO, . Male breast cancer: Pathological and immunohistochemical features. Anticancer Res1997;17:2335–8.
48.
GoughDB, DonohueJH, EvansMM, . A 50-year experience of male breast cancer: Is outcome changing?Surg Oncol1993;2:325–33.
49.
VisfeltJ, ScheikeO. Male breast cancer. I. Histologic typing and grading of 187 Danish cases. Cancer1973;32:985–90.
50.
McLachlanS, ErlichmanC, LiuF-F, . Male breast cancer: An 11 year review of 66 patients. Breast Cancer Res Treat1996;40:225–30.
51.
SpenceRAJ, MackenzieG, AndersonJR, . Long-term survival following cancer of the male breast in Northern Ireland. Cancer1985;55:648–52.
52.
HatschekT, WingrenS, CarstensenJ, HultbornR. DNA content and S-phase fraction in male breast carcinomas. Acta Oncol1994;33:609–13.
53.
YapHY, TashimaCK, BlumenscheinGR, EcklesNE. Male breast cancer: A natural history study. Cancer1979;44:748–54.
54.
CunhaF, AndreS, SoaresJ. Morphology of male breast carcinoma in the evaluation of prognosis. Pathol Res Pract1990; 186:745–50.
55.
SchuchardtU, SeegenschmiedtH, KirschnerMJ, . Adjuvant radiotherapy or breast carcinoma in men: A 20-year clinical experience. Am J Clin Oncol1996;19:330–6.
56.
AdamiH-O, HakulinenT, EwertzM, . The survival pattern in male breast cancer: An analysis of 1429 patients from the Nordic countries. Cancer1989;64:1177–82.
57.
EnginK, UnsalM. Cancer of the male breast: The Turkish experience. J Surg Oncol1993;53:128–32.
58.
ScheikeO, Male breast cancer: Factors influencing prognosis. Br J Surg1974;30:261–70.
59.
SandlerB, CarmanC, PerryRR. Cancer of the male breast. Am Surg1994;60:816–20.
60.
KinneDW. Management of male breast cancer. Oncology1991;5:45–8.
61.
PatelHZ, BuzdarAU, HortobagyiGN. Role of adjuvant chemotherapy in male breast cancer. Cancer1989;64:1583–5.
62.
BagleyCS, WesleMN, YoungRC, LippmanME. Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol1987;10:55–60.
63.
IzquierdoMA, AlonsoC, de AndresL, OjedaB. Male breast cancer: Report of a series of 50 cases. Acta Oncol1994;33: 767–71.
64.
RibieroG, SwindellR. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer1992;65:252–4.
65.
Moredo AnelliTF, AnelliA, . Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer1994;74:74–7.
66.
RosenPR, Menendez-BotetCJ, NisselbaumJS, . Estrogen receptor protein in lesions of the male breast. Cancer1976; 37:1866–8.
67.
LeclercqG, VerhestA, DeboelMC, . Oestrogen receptors in male breast cancer. Biomedicine1976;25:327–30.
68.
GuptaN, CohenJL, RosenbaumC, RaamS. Estrogen receptors in male breast cancer. Cancer1980;46:1781–4.
69.
EversonRB, LippmanME, ThompsonEB, . Clinical correlations of steroid receptors and male breast cancer. Cancer Res1980;40:991–7.
70.
FriedmanMA, HoffmanPG, DandolosEM, . Estrogen receptors in male breast cancer: Clinical and pathologic correlations. Cancer1981;47:134–7.
71.
PichA, MargariaE, ChiusaL. Proliferative activity is a significant prognostic factor in male breast carcinoma. Am J Pathol1994;145:481–9.
72.
RogersS, DayCA, FoxSB. Expression of cathespin D and estrogen receptor in male breast carcinoma. Hum Pathol1993;24: 148–51.
73.
PegoraroRJ, NirmulD, JoubertSM. Cytoplasmic and nuclear estrogen and progesterone receptors in male breast cancer. Cancer Res1982;42:4812–4.
74.
SasanoH, KimuraM, ShizawaS, . Aromatase and steroid receptors in gynecomastia and male breast carcinoma: An immunohistochemical study. J Clin Endocrinol Metab1996;81: 3063–7.
75.
TanRH, SngITY. Male breast cancer: A retrospective study with immunohistochemical analysis of hormone receptor expression. Pathology1997;29:2–6.
76.
RuffSJ, BauerJE, KeenanEJ, . Hormone receptors in male breast carcinoma. J Surg Oncol1981;18:55–9.
77.
DoneganWL. Prognostic factors: Stage and receptor status in breast cancer. Cancer1992;70:1755–64.
78.
KardasI, SeitzG, LimonJ, . Retrospective analysis of prognostic significance of the estrogen-inducible pS2 gene in male breast carcinoma. Cancer1993;72:1652–6.
79.
MorimotoT, KomakiK, YamakawaT, . Cancer of the male breast. J Surg Oncol1990;44:180–4.
80.
KallioniemiO-P, BlancoG, AlavaikkoM, . Tumour DNA ploidy as an independent prognostic factor in breast cancer. Br J Cancer1987;56:637–42.
81.
YuanJ, HennessyC, CorbettIP, . Node negative breast cancer: The prognostic value of DNA ploidy for long-term survival. Br J Surg1991;78:844–8.
82.
HedleyDW, RuggCA, GelberRD. Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer. Cancer Res1987;47:4729–35.
83.
BatsakisJG, SneigeN, El-NaggarAK. Flow cytometric (DNA content and S-phase fraction) analysis of breast cancer. Cancer1993;71:2151–3.
84.
MerkelDE, WinchesterDJ, GoldschmidtRA, . DNA flow cytometry and pathologic grading as prognostic guides in axillary lymph node-negative breast cancer. Cancer1993;72: 1926–32.
85.
McGuireWL, ClarkGM. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med1992;326:1756–61.
86.
PichA, MargariaE, ChiusaL, . DNA ploidy and p53 expression correlate with survival and cell proliferative activity in male breast carcinoma. Hum Pathol1996;27:676–82.
87.
GattusoP, ReddyVB, GreenL, . Prognostic significance of DNA ploidy in male breast carcinoma: A retrospective analysis of 32 cases. Cancer1992;70:777–80.
88.
JonassonJG, AgnarssonBA, ThorlaciusS, . Male breast cancer in Iceland. Int J Cancer1996;65:446–9.
89.
VogelsteinB. A deadly inheritance. Nature1990;348:681–2.
90.
ThorAD, MooreDHII, EdgertonSM, . Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst1992;84:845–55.
91.
NayakBK, BaralRN. p53 gene mutation in relation to p53 protein accumulation in male and female breast cancer. Neoplasma1996;43:305–10.
92.
IsolaJ, VisakorpiT, HolliK, KallioniemiO-P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative cancer patients. J Natl Cancer Inst1992;84:1109–14.
93.
AnelliA, AnelliTFM, YoungsonB, . Mutations of the p53 gene in male breast cancer. Cancer1995;75:2233–8.
94.
DawsonPJ, SchroerKR, WolmanSR. ras and p53 genes in male breast cancer. Mod Pathol1996;9:367–70.
95.
HechtJR, WongJT, RamosL, . Male breast cancers rarely overexpress p53 protein (Abstr). Proc Am Assoc Cancer Res1994;35:214.
96.
SlamonDJ, ClarkGM, WongSG, . Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science1987;235:177–82.
97.
SlamonDJ, GodolphinW, JonesLA, . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science1989;244:707–12.
98.
BlinN, KardasI, WelterC, . Expression of the c-erbB-2 proto-oncogene in male breast carcinoma: Lack of prognostic significance. Oncology1993;50:408–11.
99.
FoxSB, DayCA, RogersS. Lack of c-erbB-2 oncoprotein expression in male breast carcinoma. J Clin Pathol1991;44:960–1.
100.
NataliPG, NicotraMR, BigottiA, . Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer1990;45:457–61.
101.
DawsonPJ, PaineTM, WolmanSR. Immunocytochemical characterization of male breast cancer. Mod Pathol1992;5:621–5.
102.
WolmanSR, FeinerHD, SchinellaRA, . A retrospective analysis of breast cancer based on outcome differences. Hum Pathol1991;22:475–80.
